Protara Therapeutics (TARA)
Develops investigational therapies for cancer, lymphatic malformations, and patients receiving parenteral support.
Something off on this page? Send us feedback.
Develops TARA-002 for non-muscle-invasive bladder cancer and lymphatic malformations, alongside IV Choline Chloride for patients receiving parenteral support. The clinical-stage company has reported no product revenue.
Advances two investigational programs for cancer, rare-disease, and parenteral-support settings. Its portfolio consists of TARA-002 and IV Choline Chloride. Both programs remain investigational.
TARA-002 is a cell-based therapy in development for non-muscle-invasive bladder cancer and lymphatic malformations. IV Choline Chloride is being developed for patients receiving parenteral support.
Its current operating business entered the public market through a reverse merger after private ArTara merged with Proteon and is headquartered in New York. The company has reported no revenue since inception and says additional capital is needed to fully realize its plans.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $17.1M · Total debt $2.7M · Total assets $176.1M · Shareholders' equity $161.3M
- Revenue
- $0
- Operating income
- −$23.3M
- Net income
- −$21.7M
No dividends on record.
| Institutions | ≈ 78.24% | 46.24M shares | |
|---|---|---|---|
| 123 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.86% | 1.10M shares | |
| 7 holders · as of Jul 1, 2026 | |||
| Strategic holders | 8.81% | 5.21M shares | |
| 1 holder · as of May 15, 2026 | |||
| Other | ≈ 11.09% | 6.55M shares | |
| remainder | |||
59.10M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Janus Henderson Group PLCStrategic | 8.81% | 5.21M | filed May 15, 2026 |
Jupiter Topco LLCInstitution | 7.95% | 4.70M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 6.20% | 3.66M | as of Jun 30, 2026 |
Millennium Management LLCInstitution | 5.25% | 3.10M | as of Jun 30, 2026 |
Velan Capital Investment Management LPInstitution | 4.81% | 2.84M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 29, 2026 | Jesse Shefferman | director, officer: CEO and President | −215,687 | $4.09 |
| Apr 8, 2026 | Jacqueline Zummo | officer: Chief R&D Officer | −1,134 | $5.40 |
| Apr 1, 2026 | Jacqueline Zummo | officer: Chief R&D Officer | −22,598 | $5.26 |
- Merck
Approved systemic PD-1 therapy in BCG-unresponsive NMIBC CIS
- ImmunityBio
Approved intravesical immunotherapy combined with BCG in NMIBC CIS
- CG Oncology
Investigational intravesical oncolytic immunotherapy across NMIBC risk groups
- enGene Therapeutics
Phase 2 intravesical gene therapy for BCG-unresponsive NMIBC CIS
- UroGen Pharma
Approved intravesical mitomycin in recurrent low-grade intermediate-risk NMIBC
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Protara Therapeutics | $3.59 | −2.58% | $206.8M | — | — | — | — |
| Merck | $149.76 | −0.77% | $372.73B | 120.7 | 17.4 | 5.6 | +5.1% |
| ImmunityBio | $8.84 | −4.82% | $9.73B | — | — | 58.7 | +93.9% |
| CG Oncology | $76.45 | −1.67% | $6.86B | — | — | 1,101.0 | — |
| enGene Therapeutics | $2.02 | −1.71% | $137.3M | — | — | — | — |
| UroGen Pharma | $42.35 | −0.97% | $2.08B | — | 34.4 | 11.0 | +199.2% |
| Median | 120.7 | 25.9 | 34.9 | +93.9% |